| 1 |
P-glycoprotein
(8268 times)
|
Pharmacology
(2399 times)
|
MDR (1915 times)
BBB (474 times)
BCRP (467 times)
|
1988 Electrophoretic analysis of P-glycoproteins produced by mouse J774.2 and Chinese hamster ovary multidrug-resistant cells.
|
| 2 |
permeability glycoprotein
(134 times)
|
Pharmacology
(26 times)
|
MDR (25 times)
BCRP (9 times)
MRP1 (8 times)
|
1993 Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
|
| 3 |
phosphoglycoprotein
(16 times)
|
Neoplasms
(4 times)
|
ABC (3 times)
MDR (3 times)
BBB (2 times)
|
1997 Evaluation of P-glycoprotein expression in human oral oncogenesis: correlation with clinicopathological features.
|
| 4 |
anti-P-glycoprotein
(15 times)
|
Neoplasms
(8 times)
|
MDR (5 times)
ADCC (2 times)
CUR (2 times)
|
1993 Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
|
| 5 |
glycoprotein P
(13 times)
|
Pharmacology
(3 times)
|
MDR (6 times)
PTX (3 times)
5-HT (1 time)
|
1995 Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line.
|
| 6 |
P-glycoprotein substrate
(4 times)
|
Pharmacology
(3 times)
|
ALP (1 time)
AUC (1 time)
HIA (1 time)
|
2004 Loperamide modifies the tissue disposition kinetics of ivermectin in rats.
|
| 7 |
P-glycoprotein transporter
(4 times)
|
Neurology
(1 time)
|
AEDs (1 time)
BBB (1 time)
CSF (1 time)
|
2007 In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites.
|
| 8 |
plasma membrane glycoprotein
(4 times)
|
Gynecology
(2 times)
|
EGFR (2 times)
HB-EGF (2 times)
Rh123 (2 times)
|
1996 Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells.
|
| 9 |
P-glycoprotein multidrug transporter protein
(3 times)
|
Biology
(3 times)
|
MXR (4 times)
|
2000 Induction of the multixenobiotic defense mechanism (MXR), P-glycoprotein, in the mussel Mytilus californianus as a general cellular response to environmental stresses.
|
| 10 |
protein--P-glycoprotein
(3 times)
|
Drug Therapy
(1 time)
|
BA (1 time)
BBB (1 time)
BMECs (1 time)
|
2015 [Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease].
|
| 11 |
P-glycoprotein expression
(2 times)
|
Hematology
(1 time)
|
AML (1 time)
MDR (1 time)
MDS (1 time)
|
1991 Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype.
|
| 12 |
chemical-P-glycoprotein
(1 time)
|
Chemistry
(1 time)
|
---
|
2013 Automated extraction of information on chemical-P-glycoprotein interactions from the literature.
|
| 13 |
DNA-PKcs/Akt/GSK-3beta signaling pathway, and higher inhibition of MDR1
(1 time)
|
Neoplasms
(1 time)
|
TRAIL (1 time)
|
2015 [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
|
| 14 |
glycoprotein p-170
(1 time)
|
Endocrinology
(1 time)
|
MDR (1 time)
rMCF7 (1 time)
|
2007 Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.
|
| 15 |
overexpressing glycoprotein-P
(1 time)
|
Biochemistry
(1 time)
|
MDR (1 time)
|
2007 Natural triterpenoids from Cecropia lyratiloba are cytotoxic to both sensitive and multidrug resistant leukemia cell lines.
|
| 16 |
P-glycation protein
(1 time)
|
Cell Transformation, Neoplastic
(1 time)
|
AL (1 time)
HMGB1 (1 time)
MRP (1 time)
|
2021 Extracellular HMGB1 interacts with RAGE and promotes chemoresistance in acute leukemia cells.
|
| 17 |
P-glycoprotein efflux pump
(1 time)
|
Chemistry
(1 time)
|
GCPh (1 time)
|
2016 Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate.
|
| 18 |
P-glycoprotein inhibitor
(1 time)
|
Pharmaceutical Preparations
(1 time)
|
ABL (1 time)
VER (1 time)
|
2021 In Situ Absorption Study of Acebutolol by Modulating P-glycoprotein with Verapamil in Rats.
|
| 19 |
P-glycoprotein pump
(1 time)
|
Drug Therapy
(1 time)
|
APTT (1 time)
AUC (1 time)
CYP450 (1 time)
|
2007 Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
|
| 20 |
P-glycoprotein-170
(1 time)
|
Drug Therapy
(1 time)
|
MDR (1 time)
|
2002 P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.
|
| 21 |
P-type glycoproteins
(1 time)
|
Drug Therapy
(1 time)
|
GI (1 time)
|
2012 Pharmaceutical nanotechnology for oral delivery of anticancer drugs.
|
| 22 |
permeability drug resistance glycoprotein
(1 time)
|
Neoplasms
(1 time)
|
BC (1 time)
PgR (1 time)
SPF (1 time)
|
1995 Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers.
|
| 23 |
Permeation glycoprotein
(1 time)
|
|
---
|
2021 Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms.
|
| 24 |
pharmacophoric features responsible for the glycoprotein P
(1 time)
|
Crystallography
(1 time)
|
---
|
2021 Crystallographic studies of piperazine derivatives of 3-methyl-5-spirofluorenehydantoin in search of structural features of P-gp inhibitors.
|
| 25 |
phenotype in LoVo/Adr cells through up-regulating expression of MDR-1
(1 time)
|
Neoplasms
(1 time)
|
MDR (1 time)
|
2011 CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53.
|
| 26 |
phosphorylated glycoprotein
(1 time)
|
Pharmacology
(1 time)
|
MDR (1 time)
PCBs (1 time)
|
2003 Polychlorinated biphenyls are not substrates for the multidrug resistance transporter-1.
|
| 27 |
Pleotropic-glycoprotein
(1 time)
|
Internal Medicine
(1 time)
|
CCNU (1 time)
CR (1 time)
DTIC (1 time)
|
2008 Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
|
| 28 |
polymorphism in genes encoding different drug metabolizing enzymes, drug transporters
(1 time)
|
Medicine
(1 time)
|
---
|
2014 Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
|
| 29 |
Previous pharmacokinetic characterization of a transporter probe cocktail containing digoxin
(1 time)
|
Pharmacology
(1 time)
|
DDI (1 time)
|
2018 Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
|
| 30 |
product, phosphoglycoprotein
(1 time)
|
Brain
(1 time)
|
BBB (1 time)
DEX (1 time)
PTL (1 time)
|
2010 Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation.
|
| 31 |
pumps such as glycoprotein P
(1 time)
|
Drug Therapy
(1 time)
|
DNM (1 time)
MDR (1 time)
MRP1 (1 time)
|
2005 Trimers of N-alkylglycines are potent modulators of the multidrug resistance phenotype.
|
| 32 |
transporter--P-glycoprotein
(1 time)
|
Genetics
(1 time)
|
BPH (1 time)
DAC (1 time)
HGPIN (1 time)
|
2013 Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
|
A Search Service for Abbreviation / Long Form